Biocon Biologics to acquire Viatris biosimilars business

6 Mar 2022 , 01:33 AM

Biocon Biologics a subsidiary of Biocon announced today that it has entered into a definitive agreement with its partner Viatris Inc NASDAQ VTRS Accordingly Biocon Biologics BBL will acquire Viatris biosimilars business to create a unique fully integrated global biosimilars enterprise Viatris will receive consideration of up to USD 3335 billion including cash up to USD 2335 billion and Compulsorily Convertible Preference Shares CCPS in BBL valued at USD 1 billion